Virtus Biotech Clinical Trials ETF
Price through Nov 16, 2026 · Flows through unavailable. Figures use the latest available records, not a live quote. Fund details retrieved Nov 16, 2026. Holdings snapshot retrieved Nov 16, 2026.
This exchange-traded fund (ETF) endeavors to match the capital appreciation and income generation of the LifeSci Biotechnology Clinical Trials Index, disregarding fees and expenses. The underlying index focuses on tracking the financial progress of a carefully chosen group of biotechnology firms engaged in clinical trials. It is important to note that, as of February 27, the fund's official name transitioned from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
BBC price
Table
| Date | BBC close |
|---|---|
| Aug 17, 2026 | $53.26 |
| Aug 18, 2026 | $53.81 |
| Aug 19, 2026 | $56.02 |
| Aug 20, 2026 | $53.87 |
| Aug 21, 2026 | $54.46 |
| Aug 24, 2026 | $54.13 |
| Aug 25, 2026 | $55.76 |
| Aug 26, 2026 | $55.15 |
| Aug 27, 2026 | $55.34 |
| Aug 28, 2026 | $53.29 |
| Aug 31, 2026 | $53.05 |
| Sep 1, 2026 | $52.91 |
| Sep 2, 2026 | $53.78 |
| Sep 3, 2026 | $53.39 |
| Sep 4, 2026 | $53.71 |
| Sep 8, 2026 | $53.17 |
| Sep 9, 2026 | $51.51 |
| Sep 10, 2026 | $49.91 |
| Sep 11, 2026 | $49.38 |
| Sep 14, 2026 | $49.94 |
| Sep 15, 2026 | $48.54 |
| Sep 16, 2026 | $48.19 |
| Sep 17, 2026 | $49.25 |
| Sep 18, 2026 | $48.61 |
| Sep 21, 2026 | $48.69 |
| Sep 22, 2026 | $49.84 |
| Sep 23, 2026 | $46.65 |
| Sep 24, 2026 | $45.78 |
| Sep 25, 2026 | $45.15 |
| Sep 28, 2026 | $46.13 |
| Sep 29, 2026 | $45.85 |
| Sep 30, 2026 | $46.29 |
| Oct 1, 2026 | $45.00 |
| Oct 2, 2026 | $44.56 |
| Oct 5, 2026 | $44.61 |
| Oct 6, 2026 | $43.26 |
| Oct 7, 2026 | $43.29 |
| Oct 8, 2026 | $43.24 |
| Oct 9, 2026 | $44.15 |
| Oct 12, 2026 | $43.06 |
| Oct 13, 2026 | $40.64 |
| Oct 14, 2026 | $40.15 |
| Oct 15, 2026 | $41.16 |
| Oct 16, 2026 | $39.12 |
| Oct 19, 2026 | $40.82 |
| Oct 20, 2026 | $42.61 |
| Oct 21, 2026 | $42.42 |
| Oct 22, 2026 | $42.13 |
| Oct 23, 2026 | $41.22 |
| Oct 26, 2026 | $41.06 |
| Oct 27, 2026 | $42.87 |
| Oct 28, 2026 | $43.95 |
| Oct 29, 2026 | $43.90 |
| Oct 30, 2026 | $43.05 |
| Nov 2, 2026 | $41.78 |
| Nov 3, 2026 | $42.81 |
| Nov 4, 2026 | $43.62 |
| Nov 5, 2026 | $40.73 |
| Nov 6, 2026 | $43.02 |
| Nov 9, 2026 | $44.99 |
| Nov 10, 2026 | $44.88 |
| Nov 11, 2026 | $45.21 |
| Nov 12, 2026 | $43.14 |
| Nov 13, 2026 | $42.53 |
| Nov 16, 2026 | $40.85 |
Recent fund-flow records are unavailable, while the price has returned +5.9% so far this year. At 0.65% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | KODKODIAK SCIENCES | 2.47% | $100.73 | -9.4% | ||
| 2 | XNCRXENCOR | 2.40% | $35.40 | -4.6% | ||
| 3 | TRAXFirst Tracks Biotherapeutics | 2.14% | $46.56 | -1.1% | ||
| 4 | REPLREPLIMUNE GROUP | 1.92% | $21.41 | -2.2% | ||
| 5 | ABCLABCELLERA BIOLOGICS | 1.72% | $11.12 | -3.2% | ||
| 6 | AMLXAMYLYX PHARMACEUTICALS | 1.59% | $27.80 | -8.2% | ||
| 7 | VRDNVIRIDIAN THERAPEUTICS | 1.45% | $29.80 | -3.5% | ||
| 8 | SGPSPYGLASS PHARMA INC | 1.40% | $32.24 | -1.9% | ||
| 9 | LBRXLB PHARMACEUTICALS INC | 1.16% | $42.99 | -0.0% | ||
| 10 | PRMEPRIME MEDICINE | 1.09% | $4.19 | -1.9% | ||
| 11 | MBXMBX Biosciences | 1.19% | $53.12 | -5.0% | ||
| 12 | KYMRKYMERA THERAPEUTICS | 1.15% | $125.85 | -1.3% | ||
| 13 | CGONCG ONCOLOGY INC | 0.91% | $84.78 | +14.0% | ||
| 14 | ORKAOruka Therapeutics | 1.17% | $99.24 | -5.8% | ||
| 15 | ZBIOZenas BioPharma | 1.08% | $27.93 | -0.3% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.
Sign in to see all 198Sector weights
- Healthcare100%
- Health Technology95.08%
- Other76.48%
- Cash1.99%
- Commercial Services1.97%
- Miscellaneous1.9%
- Communications0.99%
- Finance0.96%
- Health Services0.96%
- Electronic Technology0.88%
Show as table
| Item | Value (%) |
|---|---|
| Healthcare | 100% |
| Health Technology | 95.08% |
| Other | 76.48% |
| Cash | 1.99% |
| Commercial Services | 1.97% |
| Miscellaneous | 1.9% |
| Communications | 0.99% |
| Finance | 0.96% |
| Health Services | 0.96% |
| Electronic Technology | 0.88% |
Country weights
- United States90.45%
- Other68.55%
- Canada2.33%
- Netherlands2.05%
- United Kingdom1.99%
- Germany1.53%
- Ireland1.49%
- Switzerland1.07%
Show as table
| Item | Value (%) |
|---|---|
| United States | 90.45% |
| Other | 68.55% |
| Canada | 2.33% |
| Netherlands | 2.05% |
| United Kingdom | 1.99% |
| Germany | 1.53% |
| Ireland | 1.49% |
| Switzerland | 1.07% |
| 1 week | -9.0% |
| 1 month | +4.4% |
| 3 months | -22.7% |
| 6 months | -3.7% |
| YTD | +5.9% |
| 1 year | — |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | — |
| 3 months | — |
| YTD | — |
| 1 year | — |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 2.5% of the book; the top ten carry 17%. Spread across 130+ names, it behaves like roughly 104 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| SLS SELLAS LIFE SCIENCES GROUP | $10M | $13M |
| SMMT SUMMIT THERAPEUTICS | $5M | $5M |
| CGON CG ONCOLOGY INC | $3M | $6M |
| CAPR CAPRICOR THERAPEUTICS | $906,988 | $3M |
| VKTX VIKING THERAPEUTICS | $1M | $1M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES


